0001479290-19-000010.txt : 20190123 0001479290-19-000010.hdr.sgml : 20190123 20190123213809 ACCESSION NUMBER: 0001479290-19-000010 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190122 FILED AS OF DATE: 20190123 DATE AS OF CHANGE: 20190123 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Allouche Cyril CENTRAL INDEX KEY: 0001744573 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36297 FILM NUMBER: 19538533 MAIL ADDRESS: STREET 1: 7555 GATEWAY BLVD. CITY: NEWARK STATE: CA ZIP: 94560 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Revance Therapeutics, Inc. CENTRAL INDEX KEY: 0001479290 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770551645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7555 GATEWAY BLVD. CITY: NEWARK STATE: CA ZIP: 94560 BUSINESS PHONE: 510-742-3400 MAIL ADDRESS: STREET 1: 7555 GATEWAY BLVD. CITY: NEWARK STATE: CA ZIP: 94560 4 1 wf-form4_154829747297041.xml FORM 4 X0306 4 2019-01-22 0 0001479290 Revance Therapeutics, Inc. RVNC 0001744573 Allouche Cyril C/O REVANCE THERAPEUTICS, INC. 7555 GATEWAY BLVD NEWARK CA 94560 0 1 0 0 Principal Accounting Officer Common Stock 2019-01-22 4 M 0 625 13.35 A 4625 D Common Stock 2019-01-22 4 S 0 625 17.77 D 4000 D Employee Stock Option (Right to Buy) 13.35 2019-01-22 4 M 0 625 0 D 2026-10-30 Common Stock 625.0 6875 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by Mr. Allouche. The Option vests in accordance to the following schedule: 25% on the first anniversary of the vesting commencement date of October 31, 2016, and 1/48th vesting each month thereafter for the remaining three years, subject to Mr. Allouche's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of such date. /s/ Gordon Ho, Attorney-in-Fact 2019-01-23